Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.101.23
- Author:
Ying LIU
1
;
Lei XIONG
2
;
Ruoxue CAI
1
;
Yue CHEN
1
;
Jinjun YE
1
;
Bo SHEN
1
;
Guoren ZHOU
1
Author Information
1. The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, China.
2. General Hospital of Eastern Theater Command, Nanjing 210002, China.
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
Tertiary lymphoid structure
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Tertiary Lymphoid Structures/pathology*;
Lung Neoplasms/pathology*;
Prognosis;
Immunotherapy;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2023;26(8):615-620
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of individuals can benefit from immunotherapy. Therefore, it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC. Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs (SLO), and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors, including NSCLC. This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC, in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans.
.
